Interpace Diagnostics Group (IDXG) Stock Statistics & Valuation Metrics

Interpace Diagnostics Group has a market cap or net worth of $3.89M. The enterprise value is $4.13M.

Interpace Diagnostics Group has 4,423,093 shares outstanding. The number of shares has decreased by -2.65% in one year.

Interpace Diagnostics Group’s return on equity (ROE) is -3.02 and return on invested capital (ROIC) is 95.70%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Interpace Diagnostics Group had revenue of 46.93M and earned 6.70M in profits. Earnings per share was 1.42.

In the last 12 months, operating cash flow was 5.94M and capital expenditures -848.00K, giving a free cash flow of 5.09M billion.

Interpace Diagnostics Group pays an annual dividend of ―, resulting in a dividend yield of ―

Interpace Diagnostics Group upcoming earnings date is Aug 6, 2025, After Close (Confirmed).

Interpace Diagnostics Group as a current ratio of 1.11, with Debt / Equity ratio of -185.57%

In the past 12 months, Interpace Diagnostics Group has paid 4.00K in taxes.

Interpace Diagnostics Group EV to EBITDA ratio is 1.94, with an EV/FCF ratio of 4.31.

Interpace Diagnostics Group has $1.20M in cash and marketable securities with $1.08M in debt, giving a net cash position of -$116.00K billion.

Gross margin is 64.82%, with operating margin of 17.28%, and net profit margin of 14.28%.

The average price target for Interpace Diagnostics Group is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold